Myriad Genetics, Inc. (MYGN)
ROA
Obliczenia
|
2023 (31 gru 2023) |
2022 (31 gru 2022) |
2021 (31 gru 2021) |
2020 (30 cze 2020) |
2019 (30 cze 2019) |
||
|---|---|---|---|---|---|---|
| Zysk netto | w tys. USD | -263 300 | -112 000 | -27 200 | -199 500 | 4 600 |
| Aktywa razem | w tys. USD | 1 146 500 | 1 198 700 | 1 320 700 | 1 404 600 | 1 562 700 |
| ROA | -22,97% | -9,34% | -2,06% | -14,20% | 0,29% |
2023 obliczenia
ROA = Zysk netto ÷ Aktywa razem
= $-263 300K ÷ $1 146 500K
= -22,97%
Analiza porównawcza
2023
Nazwa spółki
Symbol
ROA
Myriad Genetics, Inc.
MYGN
-22,97%
Amphastar Pharmaceuticals Inc
AMPH
9,09%
Arcus Biosciences Inc
RCUS
-28,04%
Catalyst Pharmaceuticals Inc
CPRX
15,19%
Dynavax Technologies Corp.
DVAX
-0,64%
Harmony Biosciences Holdings Inc
HRMY
15,88%
Ironwood Pharmaceuticals Inc
IRWD
-212,76%
Ligand Pharmaceuticals, Inc.
LGND
6,63%
Pacira BioSciences Inc
PCRX
2,66%
Supernus Pharmaceuticals Inc
SUPN
0,10%
Xencor Inc
XNCR
-13,23%